Class Action Alert: Pomerantz Law Firm Issues Notice on Immutep Limited Securities Case
In a significant legal development, Pomerantz LLP has announced the initiation of a class action lawsuit against Immutep Limited, a company listed on the NASDAQ under the symbol IMMP. This lawsuit comes in response to substantial losses suffered by investors who acquired Immutep securities within a specific timeframe. The law firm is urging affected investors to reach out to their offices for more details and to expand the investor claimant pool.
The lawsuit centers on claims that Immutep, along with its senior management and board members, may have engaged in securities fraud and other questionable business practices. Affected investors are encouraged to contact Danielle Peyton at Pomerantz LLP, either via email or phone, to determine if they meet the criteria to participate in the class action. Those interested are advised to include relevant contact information and details regarding their investment in Immutep shares.
The specific class period for this lawsuit spans several months, culminating in crucial deadlines for investors. Notably, a key date is set for July 6, 2026, by which potential class members can request to be appointed as Lead Plaintiff in the case. Interested individuals can access the formal Complaint through Pomerantz's online platforms to better understand the charges against Immutep.
The context of this lawsuit stems from a press release issued by Immutep on March 13, 2026. In this release, the company disclosed that the Independent Data Monitoring Committee (IDMC) had recommended discontinuing the TACTI-004 Phase III study, which evaluated eftilagimod alfa, a treatment for patients with non-small cell lung cancer. The recommendation followed an interim review based on the data available, where the IDMC deemed further continuation of the trial unwarranted due to futility.
Following the announcement, Immutep's shares plummeted dramatically. The American Depositary Receipt (ADR) price experienced a staggering drop of $2.27, equating to a loss of more than 82%. This sharp decline clearly indicates the market's reaction to the negative news regarding the clinical trial, underscoring the serious financial implications for investors and the urgency for potential class members to act promptly.
Pomerantz LLP has a reputable history in handling significant securities class actions, with over 85 years of experience advocating for investors’ rights. Founded by Abraham L. Pomerantz, who was instrumental in establishing the framework for class-action litigation, the firm has earned recognition for its tenacity and effectiveness in obtaining restitution for those affected by corporate misconduct.
For those impacted by the Immutep situation, this class action represents an opportunity to seek justice and potentially recover losses incurred due to the company's alleged misconduct. Timely action is crucial, and affected investors should consider their options carefully as the deadlines approach. Further information can be obtained by visiting their official website or contacting their office directly. This investment alert serves as a critical reminder for all stakeholders to stay informed about their rights and potential avenues for redress in light of the ongoing litigation.
The lawsuit centers on claims that Immutep, along with its senior management and board members, may have engaged in securities fraud and other questionable business practices. Affected investors are encouraged to contact Danielle Peyton at Pomerantz LLP, either via email or phone, to determine if they meet the criteria to participate in the class action. Those interested are advised to include relevant contact information and details regarding their investment in Immutep shares.
The specific class period for this lawsuit spans several months, culminating in crucial deadlines for investors. Notably, a key date is set for July 6, 2026, by which potential class members can request to be appointed as Lead Plaintiff in the case. Interested individuals can access the formal Complaint through Pomerantz's online platforms to better understand the charges against Immutep.
The context of this lawsuit stems from a press release issued by Immutep on March 13, 2026. In this release, the company disclosed that the Independent Data Monitoring Committee (IDMC) had recommended discontinuing the TACTI-004 Phase III study, which evaluated eftilagimod alfa, a treatment for patients with non-small cell lung cancer. The recommendation followed an interim review based on the data available, where the IDMC deemed further continuation of the trial unwarranted due to futility.
Following the announcement, Immutep's shares plummeted dramatically. The American Depositary Receipt (ADR) price experienced a staggering drop of $2.27, equating to a loss of more than 82%. This sharp decline clearly indicates the market's reaction to the negative news regarding the clinical trial, underscoring the serious financial implications for investors and the urgency for potential class members to act promptly.
Pomerantz LLP has a reputable history in handling significant securities class actions, with over 85 years of experience advocating for investors’ rights. Founded by Abraham L. Pomerantz, who was instrumental in establishing the framework for class-action litigation, the firm has earned recognition for its tenacity and effectiveness in obtaining restitution for those affected by corporate misconduct.
For those impacted by the Immutep situation, this class action represents an opportunity to seek justice and potentially recover losses incurred due to the company's alleged misconduct. Timely action is crucial, and affected investors should consider their options carefully as the deadlines approach. Further information can be obtained by visiting their official website or contacting their office directly. This investment alert serves as a critical reminder for all stakeholders to stay informed about their rights and potential avenues for redress in light of the ongoing litigation.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.